| Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA AR Thierry, F Mouliere, S El Messaoudi, C Mollevi, E Lopez-Crapez, ... Nature medicine 20 (4), 430-435, 2014 | 671 | 2014 |
| Pro-gastrin-releasing peptide, neuron specific enolase and chromogranin A as serum markers of small cell lung cancer PJ Lamy, J Grenier, A Kramar, JL Pujol Lung Cancer 29 (3), 197-203, 2000 | 167 | 2000 |
| Circulating cell-free DNA from colorectal cancer patients may reveal high KRAS or BRAF mutation load F Mouliere, S El Messaoudi, C Gongora, AS Guedj, B Robert, M Del Rio, ... Translational oncology 6 (3), 319-IN8, 2013 | 164 | 2013 |
| HER2 shedding and serum HER2 extracellular domain: biology and clinical utility in breast cancer C Tsé, AS Gauchez, W Jacot, PJ Lamy Cancer treatment reviews 38 (2), 133-142, 2012 | 145 | 2012 |
| Neuroendocrine and cytokeratin serum markers as prognostic determinants of small cell lung cancer JL Pujol, X Quantin, W Jacot, JM Boher, J Grenier, PJ Lamy Lung Cancer 39 (2), 131-138, 2003 | 142 | 2003 |
| Identification of a new panel of serum autoantibodies associated with the presence of in situ carcinoma of the breast in younger women C Desmetz, C Bascoul-Mollevi, P Rochaix, PJ Lamy, A Kramar, ... Clinical Cancer Research 15 (14), 4733-4741, 2009 | 128 | 2009 |
| Docetaxel and cisplatin in patients with metastatic androgen independent prostate cancer and circulating neuroendocrine markers S Culine, M El Demery, PJ Lamy, F Iborra, C Avancès, F Pinguet The Journal of urology 178 (3), 844-848, 2007 | 99 | 2007 |
| Measles Virus Exploits Dendritic Cells to Suppress CD4< sup>+</sup> T-Cell Proliferation via Expression of Surface Viral Glycoproteins Independently of T-Cell Trans-infection B Dubois, PJ Lamy, K Chemin, A Lachaux, D Kaiserlian Cellular immunology 214 (2), 173-183, 2001 | 92 | 2001 |
| Prognostic biomarkers used for localised prostate cancer management: a systematic review PJ Lamy, Y Allory, AS Gauchez, B Asselain, P Beuzeboc, P De Cremoux, ... European Urology Focus 4 (6), 790-803, 2018 | 87 | 2018 |
| Randomized phase II–III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trial JL Pujol, A Lavole, E Quoix, O Molinier, PJ Souquet, F Barlesi, H Le Caer, ... Annals of Oncology 26 (5), 908-914, 2015 | 87 | 2015 |
| Clinical practice guidelines for BRCA1 and BRCA2 genetic testing P Pujol, M Barberis, P Beer, E Friedman, JM Piulats, ED Capoluongo, ... European Journal of Cancer 146, 30-47, 2021 | 75 | 2021 |
| Quantification and clinical relevance of gene amplification at chromosome 17q12-q21 in human epidermal growth factor receptor 2-amplified breast cancers PJ Lamy, F Fina, C Bascoul-Mollevi, AC Laberenne, PM Martin, LH Ouafik, ... Breast Cancer Research 13, 1-12, 2011 | 75 | 2011 |
| SISH/CISH or qPCR as alternative techniques to FISH for determination of HER2 amplification status on breast tumors core needle biopsies: a multicenter experience based on 840 … J Jacquemier, F Spyratos, B Esterni, MJ Mozziconacci, M Antoine, ... BMC cancer 13 (1), 1-11, 2013 | 72 | 2013 |
| Autologous cell lines from circulating colon cancer cells captured from sequential liquid biopsies as model to study therapy-driven tumor changes A Soler, L Cayrefourcq, T Mazard, A Babayan, PJ Lamy, S Assou, ... Scientific reports 8 (1), 15931, 2018 | 67 | 2018 |
| KRAS Mutation Detection in Paired Frozen and Formalin-Fixed Paraffin-Embedded (FFPE) Colorectal Cancer Tissues J Solassol, J Ramos, E Crapez, M Saifi, A Mangé, E Vianès, PJ Lamy, ... International journal of molecular sciences 12 (5), 3191-3204, 2011 | 66 | 2011 |
| Progesterone receptor quantification as a strong prognostic determinant in postmenopausal breast cancer women under tamoxifen therapy PJ Lamy, P Pujol, S Thezenas, A Kramar, P Rouanet, F Guilleux, ... Breast cancer research and treatment 76, 65-71, 2002 | 66 | 2002 |
| Identification of pro-MMP-7 as a serum marker for renal cell carcinoma by use of proteomic analysis G Sarkissian, P Fergelot, PJ Lamy, JJ Patard, S Culine, P Jouin, ... Clinical chemistry 54 (3), 574-581, 2008 | 62 | 2008 |
| The HER2 amplicon in breast cancer: Topoisomerase IIA and beyond W Jacot, M Fiche, K Zaman, A Wolfer, PJ Lamy Biochimica et Biophysica Acta (BBA)-Reviews on Cancer 1836 (1), 146-157, 2013 | 59 | 2013 |
| Iron homeostasis and anemia markers in early breast cancer PJ Lamy, A Durigova, W Jacot Clinica chimica acta 434, 34-40, 2014 | 58 | 2014 |
| Identification and validation of new autoantibodies for the diagnosis of DCIS and node negative early‐stage breast cancers J Lacombe, A Mangé, M Jarlier, C Bascoul‐Mollevi, P Rouanet, PJ Lamy, ... International journal of cancer 132 (5), 1105-1113, 2013 | 58 | 2013 |
Denis PezetCHU Clermont Ferrand在 chu-clermontferrand.fr 的电子邮件经过验证
